Syros Pharmaceuticals is a life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Syros' proprietary platform identifies the master switches for disease genes, opening a whole new approach to novel therapeutics. Syros' initial focus is in cancer, but the company platform will also be applicable to other therapeutic areas.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/11/13 | $30,000,000 | Series A |
ARCH Venture Partners Flagship Ventures | undisclosed |
| 10/27/14 | $53,000,000 | Series B |
Aisling Capital Alexandria Real Estate Equities ARCH Venture Partners Flagship Ventures Polaris Partners Redmile Group WuXi Corporate Venture Fund | undisclosed |
| 01/13/16 | $40,000,000 |
Aisling Capital Alexandria Real Estate Equities Casdin Capital Deerfield Management Company, L.P. Fidelity Investments Polaris Partners Redmile Group WuXi Corporate Venture Fund | undisclosed |
